Medacta reports second-half beat, maintains 2026 guidance

Medacta has reported a strong performance for the second half of the year, exceeding market expectations. The company has also reiterated its guidance for 2026, which reassures investors about its growth trajectory. This performance indicates resilience in demand and operational execution amid economic uncertainties. The positive results are likely to boost investor sentiment and confidence in Medacta's long-term plans. Overall, the announcement reflects a bullish outlook for the company in the coming years.